Clinical Scoring Systems, Molecular Subtypes and Baseline [F]FDG PET/CT Image Analysis for Prognosis of Diffuse Large B-cell Lymphoma

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2024 Dec 19

PMID 39696503

Authors

Zhuxu Sun

Tianshuo Yang

Chongyang Ding

Yuye Shi

Luyi Cheng

Qingshen Jia

Weijing Tao

Affiliations

Soon will be listed here.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous hematological malignancy resulting in a range of outcomes, and the early prediction of these outcomes has important implications for patient management. Clinical scoring systems provide the most commonly used prognostic evaluation criteria, and the value of genetic testing has also been confirmed by in-depth research on molecular typing. [F]-fluorodeoxyglucose positron emission tomography / computed tomography ([F]FDG PET/CT) is an invaluable tool for predicting DLBCL progression. Conventional baseline image-based parameters and machine learning models have been used in prognostic FDG PET/CT studies of DLBCL; however, numerous studies have shown that combinations of baseline clinical scoring systems, molecular subtypes, and parameters and models based on baseline FDG PET/CT image may provide better predictions of patient outcomes and aid clinical decision-making in patients with DLBCL.

References

Winkelmann M, Blumenberg V, Rejeski K, Bucklein V, Ruzicka M, Unterrainer M . Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy. Eur J Nucl Med Mol Imaging. 2022; 50(5):1406-1413. DOI: 10.1007/s00259-022-06075-2. View

Weiler-Sagie M, Kagna O, Dann E, Ben-Barak A, Israel O . Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2014; 41(6):1133-40. DOI: 10.1007/s00259-014-2706-x. View

Gleeson M, Counsell N, Cunningham D, Lawrie A, Clifton-Hadley L, Hawkes E . Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. Br J Haematol. 2020; 192(6):1015-1019. DOI: 10.1111/bjh.16691. View

Susanibar-Adaniya S, Barta S . 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol. 2021; 96(5):617-629. PMC: 8172085. DOI: 10.1002/ajh.26151. View

Yhim H, Park Y, Han Y, Kim S, Kang S, Moon J . A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. Eur J Nucl Med Mol Imaging. 2018; 45(13):2274-2284. DOI: 10.1007/s00259-018-4093-1. View

Frood R, Burton C, Tsoumpas C, Frangi A, Gleeson F, Patel C . Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review. Eur J Nucl Med Mol Imaging. 2021; 48(10):3198-3220. PMC: 8426243. DOI: 10.1007/s00259-021-05233-2. View

Czibor S, Carr R, Redondo F, Auewarakul C, Cerci J, Paez D . Prognostic parameters on baseline and interim [ 18 F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients. Nucl Med Commun. 2023; 44(4):291-301. PMC: 9994851. DOI: 10.1097/MNM.0000000000001664. View

Pomykala K, Fendler W, Vermesh O, Umutlu L, Herrmann K, Seifert R . Molecular Imaging of Lymphoma: Future Directions and Perspectives. Semin Nucl Med. 2022; 53(3):449-456. DOI: 10.1053/j.semnuclmed.2022.10.003. View

Eertink J, Zwezerijnen G, Heymans M, Pieplenbosch S, Wiegers S, Duhrsen U . Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood. 2023; 141(25):3055-3064. PMC: 10646814. DOI: 10.1182/blood.2022018558. View

10.

Zhang Y, Song L, Zhao M, Hu K . A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV. Cancer Med. 2019; 8(11):5137-5147. PMC: 6718622. DOI: 10.1002/cam4.2284. View

11.

Xu H, Ma J, Yang G, Xiao S, Li W, Sun Y . Prognostic value of metabolic tumor volume and lesion dissemination from baseline PET/CT in patients with diffuse large B-cell lymphoma: Further risk stratification of the group with low-risk and high-risk NCCN-IPI. Eur J Radiol. 2023; 163:110798. DOI: 10.1016/j.ejrad.2023.110798. View

12.

Klanova M, Sehn L, Bence-Bruckler I, Cavallo F, Jin J, Martelli M . Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019; 133(9):919-926. PMC: 6396175. DOI: 10.1182/blood-2018-07-862862. View

13.

Ning N, Zhang S, Wu Q, Li X, Kuang D, Duan Y . Inhibition of acylglycerol kinase sensitizes DLBCL to venetoclax via upregulation of FOXO1-mediated BCL-2 expression. Theranostics. 2022; 12(12):5537-5550. PMC: 9330532. DOI: 10.7150/thno.72786. View

14.

Frood R, Clark M, Burton C, Tsoumpas C, Frangi A, Gleeson F . Discovery of Pre-Treatment FDG PET/CT-Derived Radiomics-Based Models for Predicting Outcome in Diffuse Large B-Cell Lymphoma. Cancers (Basel). 2022; 14(7). PMC: 8997127. DOI: 10.3390/cancers14071711. View

15.

Alderuccio J, Reis I, Hamadani M, Nachiappan M, Leslom S, Kahl B . PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial. Clin Cancer Res. 2023; 30(1):139-149. PMC: 10872617. DOI: 10.1158/1078-0432.CCR-23-1561. View

16.

Ceriani L, Milan L, Martelli M, Ferreri A, Cascione L, Zinzani P . Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood. 2018; 132(2):179-186. DOI: 10.1182/blood-2018-01-826958. View

17.

Jiang C, Li A, Teng Y, Huang X, Ding C, Chen J . Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022; 49(8):2902-2916. DOI: 10.1007/s00259-022-05717-9. View

18.

Ellin F, Maurer M, Srour L, Farooq U, Jerkeman M, Connors J . Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. Br J Haematol. 2019; 186(3):e24-e27. PMC: 7046310. DOI: 10.1111/bjh.15859. View

19.

Cottereau A, Nioche C, Dirand A, Clerc J, Morschhauser F, Casasnovas O . F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome. J Nucl Med. 2019; 61(1):40-45. PMC: 6954460. DOI: 10.2967/jnumed.119.229450. View

20.

Chantepie S, Hovhannisyan N, Guillouet S, Pelage J, Ibazizene M, Bodet-Milin C . F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients. J Nucl Med. 2018; 59(9):1380-1385. DOI: 10.2967/jnumed.117.206920. View